<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Diabetes</journal-id><journal-id journal-id-type="publisher-id">diabetes</journal-id><journal-title>Diabetes</journal-title><issn pub-type="ppub">0012-1797</issn><issn pub-type="epub">1939-327X</issn><publisher><publisher-name>American Diabetes Association</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">5792470</article-id><article-id pub-id-type="doi">10.2337/db07-0924</article-id><article-id pub-id-type="pmid">18511847</article-id><article-categories><subj-group subj-group-type="heading"><subject>Complications</subject></subj-group></article-categories><title-group><article-title>Differential Roles of Cardiomyocyte and Macrophage Peroxisome Proliferator&#x02013;Activated Receptor &#x003b3; in Cardiac Fibrosis</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Caglayan</surname><given-names>Evren</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Stauber</surname><given-names>Bradley</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Collins</surname><given-names>Alan R.</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Lyon</surname><given-names>Christopher J.</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Yin</surname><given-names>Fen</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Joey</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Rosenkranz</surname><given-names>Stephan</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Erdmann</surname><given-names>Erland</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Peterson</surname><given-names>Leif E.</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Ross</surname><given-names>Robert S.</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Tangirala</surname><given-names>Rajendra K.</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Hsueh</surname><given-names>Willa A.</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Division of Endocrinology, Diabetes and Hypertension, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California</aff><aff id="aff2"><label>2</label>Klinik III f&#x000fc;r Innere Medizin, Universit&#x000e4;t zu K&#x000f6;ln, K&#x000f6;ln, Germany</aff><aff id="aff3"><label>3</label>Division of Diabetes, Obesity and Lipids, The Methodist Hospital Research Institute, Houston, Texas</aff><aff id="aff4"><label>4</label>Center for Biostatistics, The Methodist Hospital Research Institute, Houston, Texas</aff><aff id="aff5"><label>5</label>Division of Cardiology, Department of Medicine, Veterans Affairs Medical Center and University of California, San Diego, San Diego, California</aff><author-notes><fn><p>Corresponding author: Willa A. Hsueh, <email>wahsueh&#x00040;tmhs.org</email></p></fn></author-notes><pub-date pub-type="ppub"><month>9</month><year>2008</year></pub-date><volume>57</volume><issue>9</issue><fpage>2470</fpage><lpage>2479</lpage><history><date date-type="received"><day>5</day><month>7</month><year>2007</year></date><date date-type="accepted"><day>14</day><month>5</month><year>2008</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2008, American Diabetes Association</copyright-statement><license license-type="open-access"><p>Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0/">http://creativecommons.org/licenses/by-nc-nd/3.0/</ext-link> for details.</p></license></permissions><self-uri xlink:title="pdf" xlink:href="zdb00908002470.pdf"/><abstract><p><bold>OBJECTIVE&#x02014;</bold>Cardiac fibrosis is an important component of diabetic cardiomyopathy. Peroxisome proliferator&#x02013;activated receptor &#x003b3; (PPAR&#x003b3;) ligands repress proinflammatory gene expression, including that of osteopontin, a known contributor to the development of myocardial fibrosis. We thus investigated the hypothesis that PPAR&#x003b3; ligands could attenuate cardiac fibrosis.</p><p><bold>RESEARCH DESIGN AND METHODS&#x02014;</bold>Wild-type cardiomyocyte- and macrophage-specific PPAR&#x003b3;<sup>&#x02212;/&#x02212;</sup> mice were infused with angiotensin II (AngII) to promote cardiac fibrosis and treated with the PPAR&#x003b3; ligand pioglitazone to determine the roles of cardiomyocyte and macrophage PPAR&#x003b3; in cardiac fibrosis.</p><p><bold>RESULTS&#x02014;</bold>Cardiomyocyte-specific PPAR&#x003b3;<sup>&#x02212;/&#x02212;</sup> mice (cPPAR&#x003b3;<sup>&#x02212;/&#x02212;</sup>) developed spontaneous cardiac hypertrophy with increased ventricular osteopontin expression and macrophage content, which were exacerbated by AngII infusion. Pioglitazone attenuated AngII-induced fibrosis, macrophage accumulation, and osteopontin expression in both wild-type and cPPAR&#x003b3;<sup>&#x02212;/&#x02212;</sup> mice but induced hypertrophy in a PPAR&#x003b3;-dependent manner. We pursued two mechanisms to explain the antifibrotic cardiomyocyte-PPAR&#x003b3;&#x02013;independent effects of pioglitazone: increased adiponectin expression and attenuation of proinflammatory macrophage activity. Adenovirus-expressed adiponectin had no effect on cardiac fibrosis and the PPAR&#x003b3; ligand pioglitazone did not attenuate AngII-induced cardiac fibrosis, osteopontin expression, or macrophage accumulation in monocyte-specific PPAR&#x003b3;<sup>&#x02212;/&#x02212;</sup> mice.</p><p><bold>CONCLUSIONS&#x02014;</bold>We arrived at the following conclusions: <italic>1</italic>) both cardiomyocyte-specific PPAR&#x003b3; deficiency and activation promote cardiac hypertrophy, <italic>2</italic>) both cardiomyocyte and monocyte PPAR&#x003b3; regulate cardiac macrophage infiltration, <italic>3</italic>) inflammation is a key mediator of AngII-induced cardiac fibrosis, <italic>4</italic>) macrophage PPAR&#x003b3; activation prevents myocardial macrophage accumulation, and <italic>5</italic>) PPAR&#x003b3; ligands attenuate AngII-induced cardiac fibrosis by inhibiting myocardial macrophage infiltration. These observations have important implications for potential interventions to prevent cardiac fibrosis.</p></abstract></article-meta><notes><fn-group><fn><p>Published ahead of print at <ext-link ext-link-type="uri" xlink:href="http://diabetes.diabetesjournals.org">http://diabetes.diabetesjournals.org</ext-link> on 28 May 2008.</p><p>The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked &#x0201c;advertisement&#x0201d; in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.</p></fn></fn-group></notes></front><body><p>Progressive cardiac fibrosis found in diabetic cardiomyopathy and postmyocardial infarction remodeling and during pressure overload can result in diastolic dysfunction leading to reduced myocardial contractility and, ultimately, heart failure (<xref ref-type="bibr" rid="r1">1</xref>&#x02013;<xref ref-type="bibr" rid="r4">4</xref>). Both angiotensin II (AngII) and aldosterone promote cardiac hypertrophy, inflammation, and fibrosis, whereas their antagonism improves cardiac function and decreases mortality in heart failure (<xref ref-type="bibr" rid="r5">5</xref>&#x02013;<xref ref-type="bibr" rid="r9">9</xref>). However, little is known about the cellular mechanism of these effects, and the prevalence of and mortality from heart failure continues to increase and is particularly common in subjects with diabetes (<xref ref-type="bibr" rid="r10">10</xref>). We have shown that osteopontin (OPN), a secreted inflammatory glycophosphoprotein, plays a pivotal role in cardiac fibrosis (<xref ref-type="bibr" rid="r11">11</xref>) and is often increased in the tissues of diabetic mouse models (<xref ref-type="bibr" rid="r11">11</xref>&#x02013;<xref ref-type="bibr" rid="r13">13</xref>). Ventricular OPN expression is increased during heart failure, paralleling the increase in atrial natriuretic peptide (ANP) expression, and AngII prominently upregulates OPN in cardiac cells (<xref ref-type="bibr" rid="r12">12</xref>,<xref ref-type="bibr" rid="r13">13</xref>). Moreover, OPN knockout (KO) mice develop less cardiac fibrosis than control mice (<xref ref-type="bibr" rid="r11">11</xref>) and are partially protected against streptozotocin-induced diabetic cardiomyopathy (<xref ref-type="bibr" rid="r14">14</xref>).</p><p>Peroxisome proliferator&#x02013;activated receptors (PPARs) are ligand-activated transcription factors that control expression of key genes that modulate pathways involved in fat, lipid, and glucose metabolism; inflammation; cell cycle; and immune responses (<xref ref-type="bibr" rid="r15">15</xref>). Synthetic PPAR&#x003b3; ligands are insulin sensitizers and have profound anti-inflammatory effects, one of which is to decrease OPN expression in vascular and renal cells (<xref ref-type="bibr" rid="r16">16</xref>). Therefore, we hypothesized that PPAR&#x003b3; agonists can attenuate myocardial fibrosis by reducing OPN expression in cardiomyocytes and/or macrophages, thereby decreasing cardiac inflammatory responses that can result in fibrosis. To test this hypothesis, we analyzed the effect of a PPAR&#x003b3; agonist on cardiac hypertrophy and fibrosis in an AngII-stimulated model using both cardiomyocyte- and macrophage-specific PPAR&#x003b3; KO mice and their wild-type (WT) littermate controls.</p><sec><title>RESEARCH DESIGN AND METHODS</title><sec><title>Generation of PPAR&#x003b3;-deficient mice.</title><p>Cardiomyocyte-specific PPAR&#x003b3; KO (cPPAR&#x003b3;<sup>&#x02212;/&#x02212;</sup>) mice were bred by mating homozygous PPAR&#x003b3;<sup>flox/flox</sup> DBA/2J mice (gift from Dr. F. Gonzalez) (<xref ref-type="bibr" rid="r17">17</xref>) with C3H transgenic mice expressing Cre recombinase under the control of the myosin light chain-2v (MLC2v-Cre) promoter (<xref ref-type="bibr" rid="r18">18</xref>). The F<sub>1</sub> generation was backcrossed with homozygous PPAR&#x003b3;<sup>flox/flox</sup> DBA mice to fix the PPAR&#x003b3;<sup>flox/flox</sup> genotype, and successive generations were mated with their littermates. Macrophage-specific PPAR&#x003b3; KO (mPPAR&#x003b3;<sup>&#x02212;/&#x02212;</sup>) mice (kindly provided by Dr. P. Tontonoz, University of California Los Angeles) were generated by crossing C57Bl/6 transgenic mice expressing Cre recombinase under the control of the lysozyme promoter (LysM-Cre) into homozygous PPAR&#x003b3;<sup>flox/flox</sup> C57Bl/6 mice (<xref ref-type="bibr" rid="r19">19</xref>,<xref ref-type="bibr" rid="r20">20</xref>). Mouse genotypes were determined by PCR (see the online appendix, available at <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.2337/db07-0924">http://dx.doi.org/10.2337/db07-0924</ext-link>).</p></sec><sec><title>Animal procedures.</title><p>Male mice (3 months of age) were fed chow diet (Harlan 8604) or chow diet supplemented with 2 mg pioglitazone/1g diet and, 2 days after starting diet, were infused with PBS or a pressor dose of AngII/PBS (2.5 &#x003bc;g &#x000b7; kg<sup>&#x02212;1</sup> &#x000b7; min<sup>&#x02212;1</sup>; Calbiochem) for the indicated treatment intervals by subcutaneous implantation of osmotic minipumps (DURECT) (<xref ref-type="bibr" rid="r21">21</xref>&#x02013;<xref ref-type="bibr" rid="r23">23</xref>). Systolic blood pressure (SBP) was measured weekly with a tail-cuff system (<xref ref-type="bibr" rid="r11">11</xref>). WT and cPPAR&#x003b3;<sup>&#x02212;/&#x02212;</sup> mice were assessed by echocardiography before minipump implantation and after a 6-week AngII infusion, as previously described (<xref ref-type="bibr" rid="r24">24</xref>). Heart rates were determined during echocardiography (under anesthesia) and during SBP measurements. No differences were detected between any of the groups. All animal procedures used in this study were approved by the University of California Los Angeles Animal Research Committee.</p></sec><sec><title>Morphometric analysis, cardiac fibrosis area, and macrophage content.</title><p>Coronal heart sections were cut at the ventricle equator and fixed in 10&#x00025; paraformaldehyde/PBS, paraffin embedded, and stained with Massons&#x02019; trichrome to detect collagen expression. Microscope images were displayed on a high-resolution monitor, digitized by a video frame grabber (PCVISION Plus; Imaging Technology, St. Laurent, Canada) running on an IBM-compatible computer, and areas positively staining for collagen were quantified with a morphometric analysis program (Image Pro; Media Cybernetics, Silver Spring, MD). Contiguous high-power fields comprising an entire left ventricular section were analyzed for each sample. Cardiac fibrosis area (blue area) was expressed as a percentage relative to the entire cardiac cross-sectional area. Cardiomyocyte diameters were determined from 100 random fibers by a single operator blinded to the study protocol, essentially as previously described (<xref ref-type="bibr" rid="r25">25</xref>).</p></sec><sec><title>Adiponectin overexpression.</title><p>Adenovirus expressing mouse adiponectin (Ad-APN) was generated from the full-length cDNA (<xref ref-type="bibr" rid="r26">26</xref>), subcloned with an Adenovirus Expression Vector Kit (Takara Biomedical), propagated in HEK293 cells, and purified and quantified with BD Adeno-X Virus Purification and Rapid Titer kits (BD Biosciences). Adenovirus expressing green fluorescent protein (Ad-GFP) was similarly constructed as a control. Male WT and cPPAR&#x003b3;<sup>&#x02212;/&#x02212;</sup> mice (3 months of age) were injected via tail vein with 1 &#x000d7; 10<sup>8</sup> plaque-forming units of virus 5 days before the start of a 6-week AngII infusion on chow diet. Plasma adiponectin levels were measured by ELISA (K1002&#x02013;1; B-Bridge).</p></sec><sec><title>Cardiac gene expression.</title><p>RNA was isolated from ventricular heart sections with Trizol reagent (Gibco-BRL, Rockville, MD) and subsequently processed with RNeasy Mini Kits and RNase-Free DNase (QIAGEN) to remove genomic DNA from the resulting mRNA samples. Cardiac mRNA samples were reverse transcribed with random hexamers and MultiScribe RT polymerase (Applied Biosystems). Real-time quantitative RT-PCR was performed using an ABI PRISM 7700 to measure gene expression (see online appendix for specific primer/probe sets). Gene expression values were normalized against glyceraldehyde-3-phosphate dehydrogenase.</p></sec><sec><title>Adult mouse cardiomyocyte analyses.</title><p>Adult mouse cardiomyocyte (AMCM) cultures were prepared according to Alliance for Cellular Signalling protocols (<xref ref-type="bibr" rid="r27">27</xref>). Immunohistochemistry was performed by standard procedures with specific antibodies for PPAR&#x003b3; (SA-206; Biomol) and myosin (MF 20; Developmental Studies Hybridoma Bank). Macrophage migration assays were performed in 96-well chambers (CytoSelect CBA-105; Cell Biolabs) according to the manufacturer's instructions. Briefly, clarified conditioned media from a 48-h AMCM culture was placed in the lower compartment of the chamber, and a 100-&#x003bc;l aliquot of a murine J774A.1 macrophage suspension (5 &#x000d7; 10<sup>5</sup> cells/ml) in myocyte culture medium was added to the upper compartment. After 4.5 h, migratory cells were detected with CyQuant GR Dye (Molecular Probes). Western blot analyses of AMCM protein (20 &#x003bc;g) were performed with a mouse-OPN&#x02013;specific antibody (MPIIIB; Developmental Studies Hybridoma Bank). Stimulation experiments were performed with WT and cPPAR&#x003b3;<sup>&#x02212;/&#x02212;</sup> AMCMs, which were serum-deprived for 1 h, and then stimulated with AngII and aldosterone (1 &#x003bc;mol/l each) as indicated.</p></sec><sec><title>Statistical analysis.</title><p>Data are presented as means &#x000b1; SEM. Data presented in <xref rid="f2" ref-type="fig">Figs. 2</xref>, <xref rid="f4" ref-type="fig">4</xref>, and <xref rid="f5" ref-type="fig">5</xref> were analyzed by one-way ANOVA due to their three-treatment design, using Tukey-Kramer multiple comparisons tests to determine treatment differences between individual means. Genotype differences between matched treatment groups were analyzed using two-tailed Student's <italic>t</italic> tests. In cases of unequal variance or non-normal distribution, nonparametric Mann-Whitney two-sample tests or Kruskal-Wallis one-way ANOVAs with Dunn post hoc analyses were performed to determine significant differences between individual means. A <italic>P</italic> value &#x02264;0.05 was considered statistically significant for all tests. Data presented in <xref ref-type="table" rid="t1">Tables 1</xref> and <xref ref-type="table" rid="t2">2</xref> and <xref rid="f3" ref-type="fig">Fig. 3</xref> were analyzed by two-way ANOVAs due to their 2 &#x000d7; 2 factor design, and Bonferroni post hoc analyses were used to identify differences between specific groups. In cases of unequal variance or non-normal distribution, data were analyzed using a linear regression approach in which the continuous data variables were sorted in ascending order and then assigned rank values (<italic>k</italic> &#x0003d; 1, 2 &#x02026;, <italic>n</italic>), with tied values averaged from the start to the end of the run. Ranked values were transformed into percentiles using the relationship <italic>k</italic>/(<italic>n</italic> &#x0002b; 1) and then transformed into quantiles of the standard normal distribution using the inverse cumulative normal function, resulting in a symmetric standard normal distribution with mean zero and variance one. Normal scores were regressed on indicator variables for treatment, genotype, and genotype-treament interaction. The genotype-treatment interaction variable was based on the product of genotype times treatment. For each outcome variable, the Bonferroni multiple test procedure was performed to provide <italic>t</italic> tests for all possible combinations of treatment and genotype. Bonferroni <italic>P</italic> values &#x02264;0.05 per number of tests were considered statistically significant for all analyses.</p></sec></sec><sec><title>RESULTS</title><sec><title>Cardiomyocyte-specific PPAR&#x003b3; KO (cPPAR&#x003b3;<sup>&#x02212;/&#x02212;</sup>) mice have cardiac hypertrophy.</title><p>cPPAR&#x003b3;<sup>&#x02212;/&#x02212;</sup> mice were created by crossing MLC2v Cre mice, which selectively delete floxed target genes in ventricular cardiomyocytes starting at the early stages of cardiac development (<xref ref-type="bibr" rid="r28">28</xref>), into a homozygous PPAR&#x003b3;<sup>flox/flox</sup> mouse background. Consistent with the fact that cardiac tissue contains several cell types in addition to including cardiomyocytes, cPPAR&#x003b3;<sup>&#x02212;/&#x02212;</sup> mice ventricles expressed only 37&#x00025; less PPAR&#x003b3; mRNA than those of WT littermates (<xref rid="f1" ref-type="fig">Fig. 1<italic>A</italic></xref>). However, PPAR&#x003b3; mRNA was not detectable in AMCMs isolated from cPPAR&#x003b3;<sup>&#x02212;/&#x02212;</sup>, and confocal microscopy demonstrated complete ablation of cardiomyocyte PPAR&#x003b3; protein expression (<xref rid="f1" ref-type="fig">Fig. 1<italic>B</italic></xref>). These data suggest that there is substantial PPAR&#x003b3; expression by other myocardial cell types. Cardiac PPAR&#x003b1; and PPAR&#x003b4; mRNA expression were not different in cPPAR&#x003b3;<sup>&#x02212;/&#x02212;</sup> and WT mice (data not shown), suggesting that there were no substantial changes in cardiac PPAR&#x003b1; and PPAR&#x003b4; mRNA expression to compensate for the loss of cardiomyocyte PPAR&#x003b3; expression.</p><p>cPPAR&#x003b3;<sup>&#x02212;/&#x02212;</sup> mice demonstrated normal reproduction and life expectancy with no spontaneous pathological phenotype, despite mild cardiac hypertrophy associated with increased ventricular atrial natriuretic peptide (ANP) expression (<xref ref-type="table" rid="t1">Table 1</xref>). Conversely, the PPAR&#x003b3; ligand pioglitazone increased ventricular heart&#x02013;to&#x02013;body weight ratios and ventricular ANP expression in WT, but not in cPPAR&#x003b3;<sup>&#x02212;/&#x02212;</sup>, mice (<xref ref-type="table" rid="t1">Table 1</xref>). Thus, both cardiomyocyte PPAR&#x003b3; deficiency and activation resulted in cardiac hypertrophy. Cardiomyocyte PPAR deficiency was also associated with differences in cardiomyocyte diameter and ventricular brain natriuretic peptide (BNP) expression, while pioglitazone treatment altered cardiomyocyte diameter and ventricular BNP mRNA expression and produced genotype-specific effects on heart&#x02013;to&#x02013;body weight ratios and ventricular ANP mRNA expression (<xref ref-type="table" rid="t1">Table 1</xref>, two-way ANOVA).</p><p>Neither cardiac fibrosis nor transforming growth factor (TGF)-&#x003b2;<sub>1</sub> or fibronectin gene expression, assayed as surrogate markers of cardiac fibrosis, was significantly different in cPPAR&#x003b3;<sup>&#x02212;/&#x02212;</sup> versus WT mice (<xref rid="f2" ref-type="fig">Fig. 2<italic>A</italic>&#x02013;<italic>D</italic></xref>). However, cPPAR&#x003b3;<sup>&#x02212;/&#x02212;</sup> mice demonstrated a 2.9-fold increase in cardiac expression of OPN, a proinflammatory monocyte chemoattractant, and a 1.4-fold increase in cardiac expression of CD68, a marker of macrophage accumulation (<xref rid="f2" ref-type="fig">Fig. 2<italic>E</italic> and <italic>F</italic></xref>), suggesting that cPPAR&#x003b3;<sup>&#x02212;/&#x02212;</sup> mice may have significantly increased basal myocardial inflammation, which could promote enhanced myocardial injury during exposure to cardiac stress.</p></sec><sec><title>AngII augments cPPAR&#x003b3;<sup>&#x02212;/&#x02212;</sup> versus WT mice cardiac hypertrophy and fibrosis.</title><p>To evaluate the role of cPPAR&#x003b3; in cardiac stress responses, mice were infused with AngII for 6 weeks at a dose known to cause hypertension, cardiac hypertrophy, and fibrosis without significant changes in plasma glucose or lipid levels (<xref ref-type="bibr" rid="r11">11</xref>,<xref ref-type="bibr" rid="r29">29</xref>). AngII infusion increased ventricular heart&#x02013;to&#x02013;body weight ratio and cardiomyocyte diameter in both genotypes, although cPPAR&#x003b3;<sup>&#x02212;/&#x02212;</sup> mice demonstrated significantly greater increases than their WT littermates, despite similar SBP increases in both groups (<xref ref-type="table" rid="t1">Table 1</xref>). Ventricular ANP and BNP mRNA expression was also significantly increased by AngII in both genotypes but did not significantly differ between genotypes (<xref ref-type="table" rid="t1">Table 1</xref>). Cardiac fibrosis and myocardial expression of TGF-&#x003b2;<sub>1</sub> and fibronectin, two fibrosis-related genes, also significantly increased with AngII infusion in both genotypes. However, whereas AngII induced nearly twofold more cardiac fibrosis in cPPAR&#x003b3;<sup>&#x02212;/&#x02212;</sup> than in WT mice (<xref rid="f2" ref-type="fig">Fig. 2<italic>A</italic> and <italic>B</italic></xref>), myocardial TGF-&#x003b2;<sub>1</sub> and fibronectin mRNA expression were similarly induced in both genotypes (<xref rid="f2" ref-type="fig">Fig. 2<italic>C</italic> and <italic>D</italic></xref>), suggesting that increased TGF-&#x003b2;<sub>1</sub> and fibronectin expression was not responsible for the increased cardiac fibrosis found in AngII-infused cPPAR&#x003b3;<sup>&#x02212;/&#x02212;</sup> mice. AngII also increased myocardial OPN and CD68 expression in both genotypes but more so in cPPAR&#x003b3;<sup>&#x02212;/&#x02212;</sup>mice, which had increased basal expression of these genes (PBS infusion, <xref rid="f2" ref-type="fig">Fig. 2<italic>E</italic> and <italic>F</italic></xref>). However, no changes in heart structure or function were detected by echocardiography in either genotype after AngII administration (data not shown).</p></sec><sec><title>Pioglitazone attenuates AngII-induced cardiac fibrosis.</title><p>To determine the ability of cPPAR&#x003b3; activation to attenuate AngII-induced cardiac hypertrophy and fibrosis, mice were AngII-infused with or without simultaneous treatment with the PPAR&#x003b3; ligand pioglitazone. Cardiomyocyte PPAR&#x003b3; deficiency was associated with increases in heart&#x02013;to&#x02013;body weight ratios and cardiomyocyte diameters in AngII-infused mice. Pioglitazone treatment increased heart&#x02013;to&#x02013;body weight ratios and cardiac BNP mRNA expression in AngII-infused mice but did not alter SBP, cardiomyocyte diameters, or ventricular ANP mRNA expression (<xref ref-type="table" rid="t1">Table 1</xref>, two-way ANOVA). No genotype-specific effects of pioglitazone were detected in AngII-infused mice. Pioglitazone treatment also similarly attenuated AngII-induced cardiac fibrosis (<xref rid="f2" ref-type="fig">Fig. 2<italic>A</italic> and <italic>B</italic></xref>) and myocardial expression of fibrosis-related (<xref rid="f2" ref-type="fig">Fig. 2<italic>C</italic> and <italic>D</italic></xref>) and proinflammatory (<xref rid="f2" ref-type="fig">Fig. 2<italic>E</italic> and <italic>F</italic></xref>) genes in both cPPAR&#x003b3;<sup>&#x02212;/&#x02212;</sup> mice and their WT littermate controls, suggesting that these antifibrotic and anti-inflammatory effects of pioglitazone are cardiomyocyte PPAR&#x003b3;&#x02013;independent.</p></sec><sec><title>Adiponectin does not attenuate AngII-accelerated cardiac fibrosis.</title><p>We hypothesized that the antifibrotic effect of pioglitazone on AngII-induced cardiac fibrosis could be mediated through increases in plasma adiponectin because adiponectin overexpression has been reported to attenuate cardiac hypertrophy in mice (<xref ref-type="bibr" rid="r30">30</xref>) and because pioglitazone treatment increased plasma adiponectin threefold in AngII-infused cPPAR&#x003b3;<sup>&#x02212;/&#x02212;</sup> and WT mice (AngII 10.2 &#x000b1; 2.6 &#x003bc;g/ml vs. AngII&#x0002b;Pio 33.9 &#x000b1; 17.0 &#x003bc;g/ml; <italic>P</italic> &#x0003d; 0.0003). Mice were thus injected with Ad-APN or Ad-GFP 5 days before the start of a 6-week AngII infusion. Ad-APN markedly increased plasma adiponectin levels, reaching a peak of 50 times baseline (10-fold pioglitazone induction) at 2 weeks postinjection and declining to 10-fold baseline by study end. Ad-APN attenuated AngII-induced heart&#x02013;to&#x02013;body weight ratio increases in WT mice (5.85 &#x000b1; 0.18 Ad-GFP vs. 5.21 &#x000b1; 0.15 Ad-APN; <italic>P</italic> &#x0003c; 0.05) but not in cPPAR&#x003b3;<sup>&#x02212;/&#x02212;</sup> mice (6.48 &#x000b1; 0.35 Ad-GFP vs. 6.35 &#x000b1; 0.18 Ad-APN; <italic>P</italic> &#x0003d; 0.79). However, Ad-APN did not attenuate AngII-induced cardiac fibrosis (<xref rid="f3" ref-type="fig">Fig. 3<italic>A</italic> and <italic>B</italic></xref>) or reduce myocardial OPN (<xref rid="f3" ref-type="fig">Fig. 3<italic>C</italic></xref>) or CD68 (<xref rid="f3" ref-type="fig">Fig. 3<italic>D</italic></xref>) mRNA expression in cPPAR&#x003b3;<sup>&#x02212;/&#x02212;</sup> or WT mice. Thus, the increased systemic adiponectin levels after pioglitazone treatment were not responsible for attenuation of AngII-induced cardiac fibrosis and OPN and CD68 expression previously observed in cPPAR&#x003b3;<sup>&#x02212;/&#x02212;</sup> mice with pioglitazone treatment.</p></sec><sec><title>PPAR&#x003b3;<sup>&#x02212;/&#x02212;</sup> cardiomyocytes support increased macrophage chemotaxis.</title><p>Because cPPAR&#x003b3;<sup>&#x02212;/&#x02212;</sup> mice demonstrated significantly more myocardial expression of OPN and CD68 than WT mice (<xref rid="f2" ref-type="fig">Fig. 2<italic>E</italic> and <italic>F</italic></xref>) and because macrophages have been implicated in cardiac fibrosis (<xref ref-type="bibr" rid="r31">31</xref>), we hypothesized that cPPAR&#x003b3;<sup>&#x02212;/&#x02212;</sup> OPN expression could promote monocyte accumulation within the myocardium that could in turn promote cardiac injury in response to proinflammatory stimuli. We found that AMCMs isolated from cPPAR&#x003b3;<sup>&#x02212;/&#x02212;</sup> mice expressed significantly more OPN protein than WT AMCMs (<xref rid="f4" ref-type="fig">Fig. 4<italic>A</italic></xref>). AMCM cultures were stimulated with AngII and aldosterone to simulate the cardiomyocyte environment during in vivo AngII infusion because AngII markedly induces adrenal aldosterone secretion. Both cPPAR&#x003b3;<sup>&#x02212;/&#x02212;</sup> and WT AMCMs demonstrated increased OPN mRNA expression when cultured with AngII and aldosterone, but the addition of pioglitazone prevented OPN induction only in WT AMCMs (<xref rid="f4" ref-type="fig">Fig. 4<italic>B</italic></xref>). Moreover, cPPAR&#x003b3;<sup>&#x02212;/&#x02212;</sup> AMCMs expressed over fivefold more OPN than WT AMCMs under all culture conditions, and conditioned media from cPPAR&#x003b3;<sup>&#x02212;/&#x02212;</sup> AMCMs stimulated with AngII and aldosterone induced 1.5-fold greater macrophage migration than WT AMCM supernatant (<xref rid="f4" ref-type="fig">Fig. 4<italic>C</italic></xref>). These in vitro data support in vivo observations that increased OPN expression in cPPAR<sup>&#x02212;/&#x02212;</sup> cardiomyocytes contributes to increased cardiac macrophage accumulation.</p></sec><sec><title>Attenuation of fibrosis by pioglitazone requires macrophage PPAR&#x003b3;.</title><p>Because AngII markedly enhanced cardiomyocyte OPN expression, cardiomyocyte-mediated macrophage chemotaxis (<xref rid="f4" ref-type="fig">Fig. 4<italic>B</italic> and <italic>C</italic></xref>), and in vivo macrophage recruitment (<xref ref-type="bibr" rid="r32">32</xref>), we hypothesized that pioglitazone could attenuate fibrosis via anti-inflammatory actions on macrophages. Macrophage-specific PPAR&#x003b3; KO (mPPAR&#x003b3;<sup>&#x02212;/&#x02212;</sup>) mice, previously described by Babaev et al. (<xref ref-type="bibr" rid="r33">33</xref>), were thus analyzed using the same treatment protocol to address the role of macrophage PPAR&#x003b3; in cardiac fibrosis. After 6 weeks, PBS-infused mPPAR&#x003b3;<sup>&#x02212;/&#x02212;</sup> and WT mice demonstrated similar cardiac fibrosis, and AngII-infused mPPAR&#x003b3;<sup>&#x02212;/&#x02212;</sup> and WT mice demonstrated similar cardiac fibrosis increases, which were substantially greater than in cPPAR&#x003b3;<sup>&#x02212;/&#x02212;</sup> and cPPAR&#x003b3;<sup>&#x0002b;/&#x0002b;</sup> mice (data not shown), likely due to the different genetic backgrounds of these mice. To study the effect of pioglitazone on similar levels of cardiac fibrosis in these two mouse models, mPPAR&#x003b3; mice were studied after 2 weeks of AngII infusion (<xref ref-type="table" rid="t2">Table 2</xref> and <xref rid="f5" ref-type="fig">Fig. 5<italic>A</italic></xref>), at which time they developed cardiac hypertrophy and fibrosis levels comparable with those of cPPAR&#x003b3; mice that received 6 weeks of AngII infusion (<xref ref-type="table" rid="t1">Table 1</xref> and <xref rid="f3" ref-type="fig">Fig. 3<italic>A</italic></xref>). After 2 weeks, PBS-infused mPPAR&#x003b3;<sup>&#x02212;/&#x02212;</sup> and mPPAR&#x003b3;<sup>&#x0002b;/&#x0002b;</sup> mice had similar heart&#x02013;to&#x02013;body weight ratios and cardiomyocyte diameters (<xref ref-type="table" rid="t2">Table 2</xref>), cardiac fibrosis and myocardial OPN and CD68 mRNA expression (<xref rid="f5" ref-type="fig">Fig. <italic>5A</italic>&#x02013;<italic>D</italic></xref>), and circulating monocyte levels (data not shown). Pioglitazone increased AngII-mediated cardiac hypertrophy independent of genotype in mPPAR&#x003b3; mice (<xref ref-type="table" rid="t2">Table 2</xref>, two-way ANOVA), but reduced AngII-mediated cardiac fibrosis and OPN and CD68 gene expression in mPPAR&#x003b3;<sup>&#x0002b;/&#x0002b;</sup> but not in mPPAR&#x003b3;<sup>&#x02212;/&#x02212;</sup> mice (<xref rid="f5" ref-type="fig">Fig. 5<italic>A</italic>&#x02013;<italic>D</italic></xref>). This data suggests that macrophage mPPAR&#x003b3; was required for the antifibrotic actions of pioglitazone observed in AngII-infused mPPAR&#x003b3;<sup>&#x0002b;/&#x0002b;</sup> (<xref rid="f5" ref-type="fig">Fig. 5<italic>A</italic></xref>) as well as cPPAR&#x003b3;<sup>&#x02212;/&#x02212;</sup> and cPPAR&#x003b3;<sup>&#x0002b;/&#x0002b;</sup> mice (<xref rid="f3" ref-type="fig">Fig. 3<italic>A</italic></xref>). Thus, the macrophage appears to be a key mediator of fibrosis in the heart.</p></sec></sec><sec><title>DISCUSSION</title><p>Although PPAR&#x003b3; ligands can promote edema by increasing renal sodium reabsorption to exacerbate heart failure (<xref ref-type="bibr" rid="r34">34</xref>), the metabolic and anti-inflammatory effects of these agents are implicated in cardiovascular protection (<xref ref-type="bibr" rid="r35">35</xref>). Indeed, a recent analysis of patients developing congestive heart failure with thiazolidinediones suggests that correction of heart failure is not associated with worsening of ejection fraction, which usually occurs with repeated bouts of congestive heart failure (<xref ref-type="bibr" rid="r36">36</xref>). We used an AngII-dependent cardiac fibrosis model in this study <italic>1</italic>) because AngII is a potent profibrotic factor (<xref ref-type="bibr" rid="r37">37</xref>) and patients with type 2 diabetes may have increased renin-angiotensin-aldosterone system (RAAS) activity due to increases in adipose-derived angiotensinogen (<xref ref-type="bibr" rid="r38">38</xref>) and <italic>2</italic>) because, importantly, PPAR&#x003b3; ligand effects on fibrosis could be studied in the absence of plasma glucose and lipid changes (<xref ref-type="bibr" rid="r11">11</xref>,<xref ref-type="bibr" rid="r29">29</xref>). We report herein that PPAR&#x003b3; ligands attenuate cardiac fibrosis via a mechanism that requires monocyte, but not cardiomyocyte, PPAR&#x003b3;. cPPAR&#x003b3;<sup>&#x02212;/&#x02212;</sup> mice had no apparent pathology, except for a mild cardiac hypertrophy, in the absence of an external stress. However, AngII infusion nearly doubled cardiac fibrosis and OPN expression in cPPAR&#x003b3;<sup>&#x02212;/&#x02212;</sup> mice relative to WT littermates. Isolated cPPAR&#x003b3;<sup>&#x02212;/&#x02212;</sup> AMCMs had more than a fivefold increase in OPN mRNA expression versus cPPAR&#x003b3;<sup>&#x0002b;/&#x0002b;</sup> AMCMs, and conditioned media of cPPAR&#x003b3;<sup>&#x02212;/&#x02212;</sup> AMCMs demonstrated 1.5-fold more monocyte chemoattractant activity than cPPAR&#x003b3;<sup>&#x0002b;/&#x0002b;</sup> AMCMs. Increased cPPAR&#x003b3;<sup>&#x02212;/&#x02212;</sup> cardiomyocyte OPN expression may contribute to increased monocyte accumulation both in the basal state and following AngII infusion, when inflammation plays a prominent role in cardiac fibrosis. However, noncardiomyocyte-driven inflammation appears critical to the cardiac fibrosis process in this model because pioglitazone attenuated cardiac fibrosis and ventricular OPN, TGF-&#x003b2;<sub>1</sub>, fibronectin, and CD68 mRNA expression in cPPAR&#x003b3;<sup>&#x02212;/&#x02212;</sup> and cPPAR&#x003b3;<sup>&#x0002b;/&#x0002b;</sup> mice, but not in mPPAR&#x003b3;<sup>&#x02212;/&#x02212;</sup> and mPPAR&#x003b3;<sup>&#x0002b;/&#x0002b;</sup> mice. Taken together, our data suggest that <italic>1</italic>) mechanisms contributing to initiation of cardiac hypertrophy are different from those contributing to initiation of cardiac fibrosis, <italic>2</italic>) cardiomyocyte PPAR&#x003b3; activation or deficiency contributes to cardiac hypertrophy, <italic>3</italic>) inflammation is a significant driver of AngII-induced cardiac fibrosis, <italic>4</italic>) both cardiomyocyte and macrophage PPAR&#x003b3; regulate cardiac macrophage infiltration, and <italic>5</italic>) PPAR&#x003b3; ligands attenuate AngII-induced cardiac fibrosis by inhibiting macrophage infiltration into the myocardium.</p><p>Since pioglitazone treatment prominently increased plasma adiponectin, we also examined whether increased plasma adiponectin might explain the antifibrotic effect of pioglitazone, independent of cardiomyocyte PPAR&#x003b3; activity. Cardiac hypertrophy and mortality, induced by aortic constriction or AngII infusion, is rescued by adenoviral adiponectin in adiponectin-deficient mice (<xref ref-type="bibr" rid="r30">30</xref>). However, whereas pioglitazone improved AngII-induced cardiac fibrosis and increased plasma adiponectin in both WT and cPPAR&#x003b3;<sup>&#x02212;/&#x02212;</sup> mice, adiponectin overexpression had no effect on cardiac fibrosis in either genotype and attenuated cardiac hypertrophy only in WT mice. Thus, adiponectin does not appear to impact fibrosis. The question of why cardiomyocyte PPAR&#x003b3; was required for attenuation of cardiac hypertrophy by adiponectin requires further investigation.</p><p>Cardiac PPAR&#x003b3; deficiency, in this study and previous reports, is associated with cardiac hypertrophy and greater hypertrophic responses to stress (<xref ref-type="bibr" rid="r39">39</xref>,<xref ref-type="bibr" rid="r40">40</xref>). Similar to Duan et al. (<xref ref-type="bibr" rid="r40">40</xref>), we found that PPAR&#x003b3; activation induced cardiac hypertrophy, which was not detectable by echocardiography and which occurred without spontaneous systolic or diastolic dysfunction. Cardiac hypertrophy in their model was associated with activation of the nuclear factor &#x003ba;B pathway (<xref ref-type="bibr" rid="r40">40</xref>). In their study, however, the PPAR&#x003b3; ligand rosiglitazone induced cardiac hypertrophy in both the WT and KO animals, leading the authors to conclude that cardiomyocyte PPAR&#x003b3; only partially mediated the effect. They proposed that rosiglitazone stimulated the p38 mitogen-activated protein kinase pathway to activate cardiac hypertrophy through a mechanism distinct from that mediated by cardiomyocyte PPAR&#x003b3; (<xref ref-type="bibr" rid="r40">40</xref>). Cardiac phenotype differences between the present study and that of Duan et al. may result from genetic differences in the two models (MLC2v Cre vs. &#x003b1;MHC Cre) or differences in pioglitazone versus rosiglitazone effects. Neither thiazolidinedione has been shown to cause cardiac hypertrophy in humans (<xref ref-type="bibr" rid="r41">41</xref>,<xref ref-type="bibr" rid="r42">42</xref>).</p><p>RAAS-induced inflammation contributes to the pathogenesis of cardiac fibrosis. Cardiac OPN expression is increased by activation of both cardiac AngII type 1 receptors and mineralocorticoid receptors (<xref ref-type="bibr" rid="r37">37</xref>). We previously reported that cardiac OPN expression is elevated in rodent models of cardiac hypertrophy and in ventricles of explanted hearts from humans receiving cardiac transplants (<xref ref-type="bibr" rid="r13">13</xref>). OPN promotes cardiac fibroblast attachment to the extracellular matrix (ECM), and cardiac fibroblast growth and ECM production (<xref ref-type="bibr" rid="r12">12</xref>,<xref ref-type="bibr" rid="r43">43</xref>), whereas OPN-deficient mice have attenuated cardiac fibrosis, suggesting that OPN is a key profibrotic factor in the heart (<xref ref-type="bibr" rid="r11">11</xref>,<xref ref-type="bibr" rid="r44">44</xref>,<xref ref-type="bibr" rid="r45">45</xref>). None of these studies differentiated between the contributions of cardiomyocyte versus macrophage OPN deficiency in attenuating cardiac fibrosis, although we reported that macrophage OPN deficiency attenuated AngII-accelerated atherosclerosis by decreasing macrophage attachment and chemotaxis and by promoting macrophage apoptosis (<xref ref-type="bibr" rid="r46">46</xref>).</p><p>In this study, we found that cardiac OPN expression and macrophage accumulation were markedly increased in nonstressed cPPAR&#x003b3;<sup>&#x02212;/&#x02212;</sup> mice. Although increased cardiac OPN expression could result from increased macrophage accumulation, isolated cPPAR&#x003b3;<sup>&#x02212;/&#x02212;</sup> AMCMs also expressed more OPN than WT AMCMs, suggesting that both macrophages and cardiomyocytes contribute to elevated cardiac OPN expression in cPPAR&#x003b3;<sup>&#x02212;/&#x02212;</sup> mice. We did not, however, observe increased cardiac fibrosis in nonstressed cPPAR&#x003b3;<sup>&#x02212;/&#x02212;</sup> mice, even in 1-year-old mice, indicating that the increased cardiac OPN expression was not associated with spontaneous cardiac pathology during this time frame. Because OPN is a macrophage chemoattractant, increased cardiac OPN secretion could lead to cardiac macrophage accumulation, as observed in AngII-infused mice, further increasing myocardial OPN expression and creating a vicious cycle that could escalate the cardiac fibrotic process.</p><p>This study underscores a role for macrophages in cardiac fibrosis and a possible role for PPAR&#x003b3; ligands in the inhibition of cardiac fibrosis. Pioglitazone decreased cardiac fibrosis, macrophage accumulation, and OPN expression in cPPAR&#x003b3;<sup>&#x02212;/&#x02212;</sup>, cPPAR&#x003b3;<sup>&#x0002b;/&#x0002b;</sup>, and mPPAR&#x003b3; <sup>&#x0002b;/&#x0002b;</sup> mice, suggesting that macrophage accumulation and OPN expression is a major mechanism of cardiac fibrosis induced by RAAS activation. PPAR&#x003b3; ligands suppress macrophage OPN expression (<xref ref-type="bibr" rid="r47">47</xref>), attenuate macrophage expression of several pro-inflammatory genes, and inhibit monocyte chemotaxis (<xref ref-type="bibr" rid="r48">48</xref>). Pioglitazone did not, however, attenuate cardiac fibrosis in mice with a monocyte-specific PPAR&#x003b3; deficiency, suggesting that PPAR&#x003b3; is required for the attenuation of monocyte inflammatory behavior that leads to cardiac fibrosis. Thus, the anti-inflammatory actions of PPAR&#x003b3; ligands may be useful for attenuating cardiac fibrosis and may be an adjunct therapy to RAAS inhibition. However, these putative anti-inflammatory cardiac actions of PPAR&#x003b3; need to be confirmed in humans. Further studies are also necessary to determine whether the metabolic and insulin-sensitizing effects of PPAR&#x003b3; ligands are also cardiomyocyte protective in diabetes and obesity and whether weaker insulin-sensitizing PPAR&#x003b3; ligands that cause less edema, which are currently under development, also attenuate cardiac fibrosis.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material id="PMC_1" content-type="local-data"><caption><title>Online-Only Appendix</title></caption><media mimetype="text" mime-subtype="html" xlink:href="db07-0924_index.html"/><media xlink:role="associated-file" mimetype="application" mime-subtype="msword" xlink:href="db07-0924_db07-0924[1].supplemental.doc"/></supplementary-material></sec></body><back><ack><p>This work was supported by National Heart, Lung, and Blood Institute Grant HLO46916 and National Institute of Diabetes and Digestive and Kidney Diseases Grant HLO70526 to W.H. and by Takeda Pharmaceuticals North America. E.C. was supported by the German Heart Foundation. The study was partially supported by a research grant from Takeda Pharmaceuticals North America, which also provided the pioglitazone used for this study.</p><p>We thank Sarah Duong, Van Chu, Rima Boyadjian, and Longsheng Hong for excellent technical assistance.</p></ack><ref-list><title>REFERENCES</title><ref id="r1"><label>1</label><citation citation-type="journal">Asbun J, Villarreal FJ: The pathogenesis of myocardial fibrosis in the setting of diabetic cardiomyopathy. <source>J Am Coll Cardiol</source><volume>47</volume>: <fpage>693</fpage>&#x02013;700, <year>2006</year><pub-id pub-id-type="pmid">16487830</pub-id></citation></ref><ref id="r2"><label>2</label><citation citation-type="journal">Deedwania PC: The progression from hypertension to heart failure. <source>Am J Hypertens</source><volume>10</volume>: <fpage>280S</fpage>&#x02013;288S, <year>1997</year><pub-id pub-id-type="pmid">9366285</pub-id></citation></ref><ref id="r3"><label>3</label><citation citation-type="journal">Kai H, Kuwahara F, Tokuda K, Imaizumi T: Diastolic dysfunction in hypertensive hearts: roles of perivascular inflammation and reactive myocardial fibrosis. <source>Hypertens Res</source><volume>28</volume>: <fpage>483</fpage>&#x02013;490, <year>2005</year><pub-id pub-id-type="pmid">16231753</pub-id></citation></ref><ref id="r4"><label>4</label><citation citation-type="journal">Weber KT: Are myocardial fibrosis and diastolic dysfunction reversible in hypertensive heart disease? <source>Congest Heart Fail</source><volume>11</volume>: <fpage>322</fpage>&#x02013;325, <year>2005</year><pub-id pub-id-type="pmid">16330908</pub-id></citation></ref><ref id="r5"><label>5</label><citation citation-type="journal">Diez J: Profibrotic effects of angiotensin II in the heart: a matter of mediators. <source>Hypertension</source><volume>43</volume>: <fpage>1164</fpage>&#x02013;1165, <year>2004</year><pub-id pub-id-type="pmid">15117918</pub-id></citation></ref><ref id="r6"><label>6</label><citation citation-type="journal">Dostal DE: Regulation of cardiac collagen: angiotensin and cross-talk with local growth factors. <source>Hypertension</source><volume>37</volume>: <fpage>841</fpage>&#x02013;844, <year>2001</year><pub-id pub-id-type="pmid">11244005</pub-id></citation></ref><ref id="r7"><label>7</label><citation citation-type="journal">Maggioni AP, Anand I, Gottlieb SO, Latini R, Tognoni G, Cohn JN: Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. <source>J Am Coll Cardiol</source><volume>40</volume>: <fpage>1414</fpage>&#x02013;1421, <year>2002</year><pub-id pub-id-type="pmid">12392830</pub-id></citation></ref><ref id="r8"><label>8</label><citation citation-type="journal">Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, et al., the SAVE Investigators: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. <source>N Engl J Med</source><volume>327</volume>: <fpage>669</fpage>&#x02013;677, <year>1992</year><pub-id pub-id-type="pmid">1386652</pub-id></citation></ref><ref id="r9"><label>9</label><citation citation-type="journal">Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J, the Randomized Aldactone Evaluation Study Investigators: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. <source>N Engl J Med</source><volume>341</volume>: <fpage>709</fpage>&#x02013;717, <year>1999</year><pub-id pub-id-type="pmid">10471456</pub-id></citation></ref><ref id="r10"><label>10</label><citation citation-type="journal">Levy WC, Mozaffarian D, Linker DT, Sutradhar SC, Anker SD, Cropp AB, Anand I, Maggioni A, Burton P, Sullivan MD, Pitt B, Poole-Wilson PA, Mann DL, Packer M: The Seattle Heart Failure Model: prediction of survival in heart failure. <source>Circulation</source><volume>113</volume>: <fpage>1424</fpage>&#x02013;1433, <year>2006</year><pub-id pub-id-type="pmid">16534009</pub-id></citation></ref><ref id="r11"><label>11</label><citation citation-type="journal">Collins AR, Schnee J, Wang W, Kim S, Fishbein MC, Bruemmer D, Law RE, Nicholas S, Ross RS, Hsueh WA: Osteopontin modulates angiotensin II-induced fibrosis in the intact murine heart. <source>J Am Coll Cardiol</source><volume>43</volume>: <fpage>1698</fpage>&#x02013;1705, <year>2004</year><pub-id pub-id-type="pmid">15120833</pub-id></citation></ref><ref id="r12"><label>12</label><citation citation-type="journal">Ashizawa N, Graf K, Do YS, Nunohiro T, Giachelli CM, Meehan WP, Tuan TL, Hsueh WA: Osteopontin is produced by rat cardiac fibroblasts and mediates A(II)-induced DNA synthesis and collagen gel contraction. <source>J Clin Invest</source><volume>98</volume>: <fpage>2218</fpage>&#x02013;2227, <year>1996</year><pub-id pub-id-type="pmid">8941637</pub-id></citation></ref><ref id="r13"><label>13</label><citation citation-type="journal">Graf K, Do YS, Ashizawa N, Meehan WP, Giachelli CM, Marboe CC, Fleck E, Hsueh WA: Myocardial osteopontin expression is associated with left ventricular hypertrophy. <source>Circulation</source><volume>96</volume>: <fpage>3063</fpage>&#x02013;3071, <year>1997</year><pub-id pub-id-type="pmid">9386176</pub-id></citation></ref><ref id="r14"><label>14</label><citation citation-type="other">Subramanian V, Krishnamurthy P, Singh K, Singh M: Lack of osteopontin improves cardiac function in streptozotocin-induced diabetic mice. <volume>292</volume>: <fpage>H673</fpage>&#x02013;H683, <year>2007</year></citation></ref><ref id="r15"><label>15</label><citation citation-type="journal">Blaschke F, Takata Y, Caglayan E, Law RE, Hsueh WA: Obesity, peroxisome proliferator-activated receptor, and atherosclerosis in type 2 diabetes. <source>Arterioscler Thromb Vasc Biol</source><volume>26</volume>: <fpage>28</fpage>&#x02013;40, <year>2006</year><pub-id pub-id-type="pmid">16239592</pub-id></citation></ref><ref id="r16"><label>16</label><citation citation-type="journal">Wakino S, Law RE, Hsueh WA: Vascular protective effects by activation of nuclear receptor PPARgamma. <source>J Diabetes Complications</source><volume>16</volume>: <fpage>46</fpage>&#x02013;49, <year>2002</year><pub-id pub-id-type="pmid">11872366</pub-id></citation></ref><ref id="r17"><label>17</label><citation citation-type="journal">Akiyama TE, Sakai S, Lambert G, Nicol CJ, Matsusue K, Pimprale S, Lee YH, Ricote M, Glass CK, Brewer HB, Jr, Gonzalez FJ: Conditional disruption of the peroxisome proliferator-activated receptor gamma gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux. <source>Mol Cell Biol</source><volume>22</volume>: <fpage>2607</fpage>&#x02013;2619, <year>2002</year><pub-id pub-id-type="pmid">11909955</pub-id></citation></ref><ref id="r18"><label>18</label><citation citation-type="journal">Chen J, Kubalak SW, Minamisawa S, Price RL, Becker KD, Hickey R, Ross J, Jr, Chien KR: Selective requirement of myosin light chain 2v in embryonic heart function. <source>J Biol Chem</source><volume>273</volume>: <fpage>1252</fpage>&#x02013;1256, <year>1998</year><pub-id pub-id-type="pmid">9422794</pub-id></citation></ref><ref id="r19"><label>19</label><citation citation-type="journal">Jones JR, Shelton KD, Guan Y, Breyer MD, Magnuson MA: Generation and functional confirmation of a conditional null PPARgamma allele in mice. <source>Genesis</source><volume>32</volume>: <fpage>134</fpage>&#x02013;137, <year>2002</year><pub-id pub-id-type="pmid">11857800</pub-id></citation></ref><ref id="r20"><label>20</label><citation citation-type="journal">Clausen BE, Burkhardt C, Reith W, Renkawitz R, Forster I: Conditional gene targeting in macrophages and granulocytes using LysMcre mice. <source>Transgenic Res</source><volume>8</volume>: <fpage>265</fpage>&#x02013;277, <year>1999</year><pub-id pub-id-type="pmid">10621974</pub-id></citation></ref><ref id="r21"><label>21</label><citation citation-type="journal">Daugherty A, Cassis L: Chronic Angiotensin II Infusion Promotes Atherogenesis in Low Density Lipoprotein Receptor &#x02212;/&#x02212; Mice. <source>Ann N Y Acad Sci</source><volume>892</volume>: <fpage>108</fpage>&#x02013;118, <year>1999</year><pub-id pub-id-type="pmid">10842656</pub-id></citation></ref><ref id="r22"><label>22</label><citation citation-type="journal">Daugherty A, Manning MW, Cassis LA: Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. <source>J Clin Invest</source><volume>105</volume>: <fpage>1605</fpage>&#x02013;1612, <year>2000</year><pub-id pub-id-type="pmid">10841519</pub-id></citation></ref><ref id="r23"><label>23</label><citation citation-type="journal">Weiss D, Kools JJ, Taylor WR: Angiotensin II-Induced Hypertension Accelerates the Development of Atherosclerosis in ApoE-Deficient Mice. <source>Circulation</source><volume>103</volume>: <fpage>448</fpage>&#x02013;454, <year>2001</year><pub-id pub-id-type="pmid">11157699</pub-id></citation></ref><ref id="r24"><label>24</label><citation citation-type="journal">Xiao G, Mao S, Baumgarten G, Serrano J, Jordan MC, Roos KP, Fishbein MC, MacLellan WR: Inducible activation of c-Myc in adult myocardium in vivo provokes cardiac myocyte hypertrophy and reactivation of DNA synthesis. <source>Circ Res</source><volume>89</volume>: <fpage>1122</fpage>&#x02013;1129, <year>2001</year><pub-id pub-id-type="pmid">11739276</pub-id></citation></ref><ref id="r25"><label>25</label><citation citation-type="journal">Ishikawa S, Fattal GA, Popiewicz J, Wyatt JP: Functional morphometry of myocardial fibers in cor pulmonale. <source>Am Rev Respir Dis</source><volume>105</volume>: <fpage>358</fpage>&#x02013;367, <year>1972</year><pub-id pub-id-type="pmid">4258862</pub-id></citation></ref><ref id="r26"><label>26</label><citation citation-type="journal">Satoh H, Nguyen MT, Trujillo M, Imamura T, Usui I, Scherer PE, Olefsky JM: Adenovirus-mediated adiponectin expression augments skeletal muscle insulin sensitivity in male Wistar rats. <source>Diabetes</source><volume>54</volume>: <fpage>1304</fpage>&#x02013;1313, <year>2005</year><pub-id pub-id-type="pmid">15855314</pub-id></citation></ref><ref id="r27"><label>27</label><citation citation-type="journal">Sambrano GR, Fraser I, Han H, Ni Y, O'Connell T, Yan Z, Stull JT: Navigating the signalling network in mouse cardiac myocytes. <source>Nature</source><volume>420</volume>: <fpage>712</fpage>&#x02013;714, <year>2002</year><pub-id pub-id-type="pmid">12478303</pub-id></citation></ref><ref id="r28"><label>28</label><citation citation-type="journal">Henderson SA, Goldhaber JI, So JM, Han T, Motter C, Ngo A, Chantawansri C, Ritter MR, Friedlander M, Nicoll DA, Frank JS, Jordan MC, Roos KP, Ross RS, Philipson KD: functional adult myocardium in the absence of Na&#x0002b;-Ca2&#x0002b; exchange: cardiac-specific knockout of NCX1. <source>Circ Res</source><volume>95</volume>: <fpage>604</fpage>&#x02013;611, <year>2004</year><pub-id pub-id-type="pmid">15308581</pub-id></citation></ref><ref id="r29"><label>29</label><citation citation-type="journal">Takata Y, Chu V, Collins AR, Lyon CJ, Wang W, Blaschke F, Bruemmer D, Caglayan E, Daley W, Higaki J, Fishbein MC, Tangirala RK, Law RE, Hsueh WA: Transcriptional repression of ATP-binding cassette transporter A1 gene in macrophages: a novel atherosclerotic effect of angiotensin II. <source>Circ Res</source><volume>97</volume>: <fpage>e88</fpage>&#x02013;e96, <year>2005</year><pub-id pub-id-type="pmid">16224068</pub-id></citation></ref><ref id="r30"><label>30</label><citation citation-type="journal">Shibata R, Ouchi N, Ito M, Kihara S, Shiojima I, Pimentel DR, Kumada M, Sato K, Schiekofer S, Ohashi K, Funahashi T, Colucci WS, Walsh K: Adiponectin-mediated modulation of hypertrophic signals in the heart. <source>Nat Med</source><volume>10</volume>: <fpage>1384</fpage>&#x02013;1389, <year>2004</year><pub-id pub-id-type="pmid">15558058</pub-id></citation></ref><ref id="r31"><label>31</label><citation citation-type="journal">Moriwaki H, Stempien-Otero A, Kremen M, Cozen AE, Dichek DA: Overexpression of urokinase by macrophages or deficiency of plasminogen activator inhibitor type 1 causes cardiac fibrosis in mice. <source>Circ Res</source><volume>95</volume>: <fpage>637</fpage>&#x02013;644, <year>2004</year><pub-id pub-id-type="pmid">15297377</pub-id></citation></ref><ref id="r32"><label>32</label><citation citation-type="journal">Zhao W, Ahokas RA, Weber KT, Sun Y: ANG II-induced cardiac molecular and cellular events: role of aldosterone. <source>Am J Physiol Heart Circ Physiol</source><volume>291</volume>: <fpage>H336</fpage>&#x02013;H343, <year>2006</year><pub-id pub-id-type="pmid">16489102</pub-id></citation></ref><ref id="r33"><label>33</label><citation citation-type="other">Babaev VR, Yancey PG, Ryzhov SV, Kon V, Breyer MD, Magnuson MA, Fazio S, Linton MF: Conditional knockout of macrophage PPARgamma increases atherosclerosis in C57BL/6 and low-density lipoprotein receptor-deficient mice. <volume>25</volume>: <fpage>1647</fpage>&#x02013;1653, <year>2005</year></citation></ref><ref id="r34"><label>34</label><citation citation-type="journal">Guan Y, Hao C, Cha DR, Rao R, Lu W, Kohan DE, Magnuson MA, Redha R, Zhang Y, Breyer MD: Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. <source>Nat Med</source><volume>11</volume>: <fpage>861</fpage>&#x02013;866, <year>2005</year><pub-id pub-id-type="pmid">16007095</pub-id></citation></ref><ref id="r35"><label>35</label><citation citation-type="journal">Caglayan E, Blaschke F, Takata Y, Hsueh WA: Metabolic syndrome-interdependence of the cardiovascular and metabolic pathways. <source>Curr Opin Pharmacol</source><volume>5</volume>: <fpage>135</fpage>&#x02013;142, <year>2005</year><pub-id pub-id-type="pmid">15780821</pub-id></citation></ref><ref id="r36"><label>36</label><citation citation-type="journal">Lago RM, Singh PP, Nesto RW: Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. <source>Lancet</source><volume>370</volume>: <fpage>1129</fpage>&#x02013;1136, <year>2007</year><pub-id pub-id-type="pmid">17905165</pub-id></citation></ref><ref id="r37"><label>37</label><citation citation-type="journal">Schnee JM, Hsueh WA: Angiotensin II, adhesion, and cardiac fibrosis. <source>Cardiovasc Res</source><volume>46</volume>: <fpage>264</fpage>&#x02013;268, <year>2000</year><pub-id pub-id-type="pmid">10773230</pub-id></citation></ref><ref id="r38"><label>38</label><citation citation-type="journal">Engeli S, Bohnke J, Gorzelniak K, Janke J, Schling P, Bader M, Luft FC, Sharma AM: Weight loss and the renin-angiotensin-aldosterone system. <source>Hypertension</source><volume>45</volume>: <fpage>356</fpage>&#x02013;362, <year>2005</year><pub-id pub-id-type="pmid">15630041</pub-id></citation></ref><ref id="r39"><label>39</label><citation citation-type="journal">Asakawa M, Takano H, Nagai T, Uozumi H, Hasegawa H, Kubota N, Saito T, Masuda Y, Kadowaki T, Komuro I: Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo. <source>Circulation</source><volume>105</volume>: <fpage>1240</fpage>&#x02013;1246, <year>2002</year><pub-id pub-id-type="pmid">11889020</pub-id></citation></ref><ref id="r40"><label>40</label><citation citation-type="journal">Duan SZ, Ivashchenko CY, Russell MW, Milstone DS, Mortensen RM: Cardiomyocyte-specific knockout and agonist of peroxisome proliferator-activated receptor-gamma both induce cardiac hypertrophy in mice. <source>Circ Res</source><volume>97</volume>: <fpage>372</fpage>&#x02013;379, <year>2005</year><pub-id pub-id-type="pmid">16051889</pub-id></citation></ref><ref id="r41"><label>41</label><citation citation-type="journal">St. John Sutton M, Rendell M, Dandona P, Dole JF, Murphy K, Patwardhan R, Patel J, Freed M: A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. <source>Diabetes Care</source><volume>25</volume>: <fpage>2058</fpage>&#x02013;2064, <year>2002</year><pub-id pub-id-type="pmid">12401757</pub-id></citation></ref><ref id="r42"><label>42</label><citation citation-type="journal">Horio T, Suzuki M, Suzuki K, Takamisawa I, Hiuge A, Kamide K, Takiuchi S, Iwashima Y, Kihara S, Funahashi T, Yoshimasa Y, Kawano Y: Pioglitazone improves left ventricular diastolic function in patients with essential hypertension. <source>Am J Hypertens</source><volume>18</volume>: <fpage>949</fpage>&#x02013;957, <year>2005</year><pub-id pub-id-type="pmid">16053992</pub-id></citation></ref><ref id="r43"><label>43</label><citation citation-type="journal">Kawano H, Cody RJ, Graf K, Goetze S, Kawano Y, Schnee J, Law RE, Hsueh WA: Angiotensin II enhances integrin and alpha-actinin expression in adult rat cardiac fibroblasts. <source>Hypertension</source><volume>35</volume>: <fpage>273</fpage>&#x02013;279, <year>2000</year><pub-id pub-id-type="pmid">10642310</pub-id></citation></ref><ref id="r44"><label>44</label><citation citation-type="journal">Trueblood NA, Xie Z, Communal C, Sam F, Ngoy S, Liaw L, Jenkins AW, Wang J, Sawyer DB, Bing OH, Apstein CS, Colucci WS, Singh K: Exaggerated left ventricular dilation and reduced collagen deposition after myocardial infarction in mice lacking osteopontin. <source>Circ Res</source><volume>88</volume>: <fpage>1080</fpage>&#x02013;1087, <year>2001</year><pub-id pub-id-type="pmid">11375279</pub-id></citation></ref><ref id="r45"><label>45</label><citation citation-type="journal">Matsui Y, Jia N, Okamoto H, Kon S, Onozuka H, Akino M, Liu L, Morimoto J, Rittling SR, Denhardt D, Kitabatake A, Uede T: Role of osteopontin in cardiac fibrosis and remodeling in angiotensin II-induced cardiac hypertrophy. <source>Hypertension</source><volume>43</volume>: <fpage>1195</fpage>&#x02013;1201, <year>2004</year><pub-id pub-id-type="pmid">15123578</pub-id></citation></ref><ref id="r46"><label>46</label><citation citation-type="journal">Bruemmer D, Collins AR, Noh G, Wang W, Territo M, Arias-Magallona S, Fishbein MC, Blaschke F, Kintscher U, Graf K, Law RE, Hsueh WA: Angiotensin II-accelerated atherosclerosis and aneurysm formation is attenuated in osteopontin-deficient mice. <source>J Clin Invest</source><volume>112</volume>: <fpage>1318</fpage>&#x02013;1331, <year>2003</year><pub-id pub-id-type="pmid">14597759</pub-id></citation></ref><ref id="r47"><label>47</label><citation citation-type="journal">Oyama Y, Akuzawa N, Nagai R, Kurabayashi M: PPARgamma ligand inhibits osteopontin gene expression through interference with binding of nuclear factors to A/T-rich sequence in THP-1 cells. <source>Circ Res</source><volume>90</volume>: <fpage>348</fpage>&#x02013;355, <year>2002</year><pub-id pub-id-type="pmid">11861425</pub-id></citation></ref><ref id="r48"><label>48</label><citation citation-type="journal">Kintscher U, Goetze S, Wakino S, Kim S, Nagpal S, Chandraratna RA, Graf K, Fleck E, Hsueh WA, Law RE: Peroxisome proliferator-activated receptor and retinoid X receptor ligands inhibit monocyte chemotactic protein-1-directed migration of monocytes. <source>Eur J Pharmacol</source><volume>401</volume>: <fpage>259</fpage>&#x02013;270, <year>2000</year><pub-id pub-id-type="pmid">10936484</pub-id></citation></ref></ref-list></back><floats-wrap><fig position="float" id="f1"><label>FIG. 1.</label><caption><p>PPAR&#x003b3; expression in cardiac ventricles and AMCMs. <italic>A</italic>: Real-time quantitative RT-PCR of ventricular tissue of 4-month-old male WT and cPPAR&#x003b3;<sup>&#x02212;/&#x02212;</sup> mice and pooled AMCMs from male WT (black bars) and cPPAR&#x003b3;<sup>&#x02212;/&#x02212;</sup> (gray bars) hearts (<italic>n</italic> &#x0003d; 3/genotype; <italic>P</italic> &#x0003c; 0.05 by Student's <italic>t</italic> test). Values are normalized to the WT group. <italic>B</italic>: Immunohistochemistry of AMCMs of male WT and cPPAR&#x003b3;<sup>&#x02212;/&#x02212;</sup> (KO) mice. Cardiomyocytes shown are representative of at least three independent experiments. (Please see <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.2337/db07-0924">http://dx.doi.org/10.2337/db07-0924</ext-link> for a high-quality digital representation of this figure.)</p></caption><graphic xlink:href="zdb0090854300001"></graphic></fig><fig position="float" id="f2"><label>FIG. 2.</label><caption><p>Pioglitazone treatment similarly attenuates fibrosis and pro-inflammatory gene expression in AngII-infused cPPAR&#x003b3;<sup>&#x02212;/&#x02212;</sup> and WT mice. <italic>A</italic>: Cardiac fibrosis was quantified by measuring midventricular collagen area (<italic>n</italic> &#x0003d; 5&#x02013;13/treatment group). <italic>B</italic>: Representative images of cardiac collagen expression (blue area) in AngII- and AngII&#x0002b;Pio-treated mice. Ventricular TGF-&#x003b2;<sub>1</sub> (<italic>n</italic> &#x0003d; 6&#x02013;13/treatment group) (<italic>C</italic>), fibronectin (<italic>n</italic> &#x0003d; 5&#x02013;14/treatment group) (<italic>D</italic>), OPN (<italic>n</italic> &#x0003d; 6&#x02013;12/treatment group) (<italic>E</italic>), and CD68 (<italic>n</italic> &#x0003d; 5&#x02013;15/treatment group) (<italic>F</italic>) mRNA expression was measured by real-time quantitative RT-PCR. Black and gray bars indicate cPPAR&#x003b3; WT and KO animal data, respectively. &#x0002a;<italic>P</italic> &#x0003c; 0.05 vs. WT by Student's <italic>t</italic> test; &#x02020;<italic>P</italic> &#x0003c; 0.05 vs. PBS and &#x02021;<italic>P</italic> &#x0003c; 0.05 vs. AngII by one-way ANOVA. Pio, pioglitazone. (Please see <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.2337/db07-0924">http://dx.doi.org/10.2337/db07-0924</ext-link> for a high-quality digital representation of this figure.)</p></caption><graphic xlink:href="zdb0090854300002"></graphic></fig><fig position="float" id="f3"><label>FIG. 3.</label><caption><p>Adiponectin does not mediate the antifibrotic effect of pioglitazone in the heart. Male cPPAR&#x003b3; mice were infected with adenovirus overexpressing Ad-GFP or Ad-APN (<italic>n</italic> &#x0003d; 4&#x02013;5/treatment group) 5 days before the start of a 6-week AngII infusion on chow diet. Cardiac fibrosis was quantified by measuring midventricular collagen expression area (<italic>A</italic>), and representative images of collagen expression (blue area) (<italic>B</italic>) are shown for each group. Cardiac OPN (<italic>C</italic>) and CD68 (<italic>D</italic>) mRNA expression in cPPAR&#x003b3;<sup>&#x02212;/&#x02212;</sup> and WT mice (<italic>n</italic> &#x0003d; 3&#x02013;5/treatment group) was measured by real-time quantitative RT-PCR. AngII-mediated increases in cardiac fibrosis, OPN, and CD68 expression were not significantly attenuated in cPPAR&#x003b3;<sup>&#x02212;/&#x02212;</sup> or WT mice injected with Ad-GFP vs. Ad-APN, and adenovirus effects did not differ according to genotype (<italic>P</italic> &#x0003e; 0.05 by two-way ANOVA). Values for WT mice are depicted by black bars and cPPAR&#x003b3;<sup>&#x02212;/&#x02212;</sup> values by gray bars. (Please see <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.2337/db07-0924">http://dx.doi.org/10.2337/db07-0924</ext-link> for a high-quality digital representation of this figure.)</p></caption><graphic xlink:href="zdb0090854300003"></graphic></fig><fig position="float" id="f4"><label>FIG. 4.</label><caption><p>PPAR&#x003b3;<sup>&#x02212;/&#x02212;</sup> cardiomyocytes have increased OPN expression. <italic>A</italic>: Representative Western blot and graph of &#x003b2;-actin normalized OPN expression in cultured AMCMs (24 h) isolated from 10-month WT and cPPAR&#x003b3;<sup>&#x02212;/&#x02212;</sup> mice (&#x0002a;<italic>P</italic> &#x0003c; 0.05 vs. WT by Student's <italic>t</italic> test). <italic>B</italic>: OPN mRNA expression in AMCMs (<italic>n</italic> &#x0003d; 3/treatment group) after 24 h culture with 0.1&#x00025; DMSO (control) or AngII and aldosterone (AngII&#x0002b;Aldo, 1 &#x003bc;mol/l each) with or without 1 &#x003bc;mol/l pioglitazone. WT values are depicted by black bars and cPPAR&#x003b3;<sup>&#x02212;/&#x02212;</sup> values by gray bars (&#x0002a;<italic>P</italic> &#x0003c; 0.05 vs. control and &#x02020;<italic>P</italic> &#x0003c; 0.05 vs. AngII&#x0002b;Aldo by one-way ANOVA). <italic>C</italic>: Mouse J774A.1 macrophage migration in response to 48-h conditioned media isolated from cPPAR&#x003b3;<sup>&#x02212;/&#x02212;</sup> (KO) and WT AMCM cultures. Nonconditioned myocyte culture media supplemented with (OPN) or without (control) 20 &#x003bc;g/ml recombinant mouse OPN served as positive and negative controls, respectively. Data are presented as &#x00025; control (&#x0002a;<italic>P</italic> &#x0003c; 0.05 vs. control; &#x02020;<italic>P</italic> &#x0003c; 0.05 vs. WT by one-way ANOVA). Pio, pioglitazone.</p></caption><graphic xlink:href="zdb0090854300004"></graphic></fig><fig position="float" id="f5"><label>FIG. 5.</label><caption><p>Pioglitazone treatment attenuates fibrosis and pro-inflammatory gene expression in AngII-infused mPPAR&#x003b3;<sup>&#x0002b;/&#x0002b;</sup>, but not mPPAR&#x003b3;<sup>&#x02212;/&#x02212;</sup>, mice. <italic>A</italic>: Cardiac fibrosis quantified by midventricular collagen area (<italic>n</italic> &#x0003d; 7&#x02013;12/treatment group). <italic>B</italic>: Representative images of cardiac collagen expression (blue area). Ventricular OPN (<italic>C</italic>) and CD68 (<italic>D</italic>) mRNA expression were measured by real-time quantitative RT-PCR (<italic>n</italic> &#x0003d; 3&#x02013;12/treatment group). Black and gray bars indicate WT and mPPAR&#x003b3;<sup>&#x02212;/&#x02212;</sup> mouse data, respectively. &#x0002a;<italic>P</italic> &#x0003c; 0.05 vs. WT by Student's <italic>t</italic> test; &#x02020;<italic>P</italic> &#x0003c; 0.05 vs. PBS; and &#x02021;<italic>P</italic> &#x0003c; 0.05 vs. AngII by one-way ANOVA. Pio, pioglitazone. (Please see <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.2337/db07-0924">http://dx.doi.org/10.2337/db07-0924</ext-link> for a high-quality digital representation of this figure.)</p></caption><graphic xlink:href="zdb0090854300005"></graphic></fig><table-wrap position="float" id="t1"><label>TABLE 1</label><caption><p>Cardiac hypertrophy in cPPAR&#x003b3; mice</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="2" align="center" valign="bottom">Treatment</th><th colspan="2" rowspan="1" align="center" valign="bottom">SBP (mmHg)<xref ref-type="table-fn" rid="t1fn3">&#x0002a;</xref><hr/></th><th colspan="3" rowspan="1" align="center" valign="bottom">Heart&#x02013;to&#x02013;body wt ratio (mg/g) <hr/></th><th colspan="3" rowspan="1" align="center" valign="bottom">Cardiomyocyte diameter (&#x003bc;m) <hr/></th><th colspan="3" rowspan="1" align="center" valign="bottom">ANP/GAPDH mRNA expression <hr/></th><th colspan="3" rowspan="1" align="center" valign="bottom">BNP/GAPDH mRNA expression <hr/></th></tr><tr><th colspan="1" rowspan="1" align="center" valign="bottom">WT</th><th colspan="1" rowspan="1" align="center" valign="bottom">KO</th><th colspan="1" rowspan="1" align="center" valign="bottom">WT</th><th colspan="1" rowspan="1" align="center" valign="bottom">KO</th><th colspan="1" rowspan="1" align="center" valign="bottom">Two-way ANOVA</th><th colspan="1" rowspan="1" align="center" valign="bottom">WT</th><th colspan="1" rowspan="1" align="center" valign="bottom">KO</th><th colspan="1" rowspan="1" align="center" valign="bottom">Two-way ANOVA</th><th colspan="1" rowspan="1" align="center" valign="bottom">WT</th><th colspan="1" rowspan="1" align="center" valign="bottom">KO</th><th colspan="1" rowspan="1" align="center" valign="bottom">Two-way ANOVA</th><th colspan="1" rowspan="1" align="center" valign="bottom">WT</th><th colspan="1" rowspan="1" align="center" valign="bottom">KO</th><th colspan="1" rowspan="1" align="center" valign="bottom">Two-way ANOVA</th></tr></thead><tbody><tr><td colspan="1" rowspan="1" align="left" valign="top">PBS&#x0002b;chow diet</td><td colspan="1" rowspan="1" align="center" valign="top">111 &#x000b1; 3 (9)</td><td colspan="1" rowspan="1" align="center" valign="top">109 &#x000b1; 4 (8)</td><td colspan="1" rowspan="1" align="center" valign="top">3.8 &#x000b1; 0.1 (9)</td><td colspan="1" rowspan="1" align="center" valign="top">4.2 &#x000b1; 0.1 (8)<xref ref-type="table-fn" rid="t1fn1">&#x02020;</xref></td><td colspan="1" rowspan="1" align="center" valign="top">Interaction</td><td colspan="1" rowspan="1" align="center" valign="top">11.4 &#x000b1; 0.2 (7)</td><td colspan="1" rowspan="1" align="center" valign="top">12.7 &#x000b1; 0.1 (6)</td><td colspan="1" rowspan="1" align="center" valign="top">Gene, drug</td><td colspan="1" rowspan="1" align="center" valign="top">0.7 &#x000b1; 0.2 (6)</td><td colspan="1" rowspan="1" align="center" valign="top">5.8 &#x000b1; 0.7 (9)</td><td colspan="1" rowspan="1" align="center" valign="top">Gene, drug, interaction</td><td colspan="1" rowspan="1" align="center" valign="top">0.7 &#x000b1; 0.1 (9)</td><td colspan="1" rowspan="1" align="center" valign="top">1.0 &#x000b1; 0.1 (8)</td><td colspan="1" rowspan="1" align="center" valign="top">Drug</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">PBS&#x0002b;Pio</td><td colspan="1" rowspan="1" align="center" valign="top">106 &#x000b1; 3 (9)</td><td colspan="1" rowspan="1" align="center" valign="top">108 &#x000b1; 2 (9)</td><td colspan="1" rowspan="1" align="center" valign="top">4.2 &#x000b1; 0.1 (9)<xref ref-type="table-fn" rid="t1fn2">&#x02021;</xref></td><td colspan="1" rowspan="1" align="center" valign="top">4.0 &#x000b1; 0.1 (9)</td><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top">12.1 &#x000b1; 0.2 (8)</td><td colspan="1" rowspan="1" align="center" valign="top">12.5 &#x000b1; 0.2 (5)</td><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top">13.1 &#x000b1; 4.0 (9)<xref ref-type="table-fn" rid="t1fn2">&#x02021;</xref></td><td colspan="1" rowspan="1" align="center" valign="top">8.4 &#x000b1; 2.6 (8)</td><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top">1.2 &#x000b1; 0.2 (10)</td><td colspan="1" rowspan="1" align="center" valign="top">1.4 &#x000b1; 0.2 (6)</td><td colspan="1" rowspan="1" align="center" valign="top"/></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">AngII&#x0002b;chow diet</td><td colspan="1" rowspan="1" align="center" valign="top">161 &#x000b1; 5 (10)</td><td colspan="1" rowspan="1" align="center" valign="top">170 &#x000b1; 5 (17)</td><td colspan="1" rowspan="1" align="center" valign="top">4.6 &#x000b1; 0.2 (13)</td><td colspan="1" rowspan="1" align="center" valign="top">5.3 &#x000b1; 0.2 (15)<xref ref-type="table-fn" rid="t1fn1">&#x02020;</xref></td><td colspan="1" rowspan="1" align="center" valign="top">Gene, drug</td><td colspan="1" rowspan="1" align="center" valign="top">13.5 &#x000b1; 0.2 (10)</td><td colspan="1" rowspan="1" align="center" valign="top">14.4 &#x000b1; 0.2 (15)<xref ref-type="table-fn" rid="t1fn1">&#x02020;</xref></td><td colspan="1" rowspan="1" align="center" valign="top">Gene</td><td colspan="1" rowspan="1" align="center" valign="top">21.8 &#x000b1; 4.9 (8)</td><td colspan="1" rowspan="1" align="center" valign="top">40.6 &#x000b1; 6.4 (9)</td><td colspan="1" rowspan="1" align="center" valign="top">&#x02014;</td><td colspan="1" rowspan="1" align="center" valign="top">1.7 &#x000b1; 0.3 (11)</td><td colspan="1" rowspan="1" align="center" valign="top">2.2 &#x000b1; 0.3 (12)</td><td colspan="1" rowspan="1" align="center" valign="top">Drug</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">AngII&#x0002b;Pio</td><td colspan="1" rowspan="1" align="center" valign="top">153 &#x000b1; 5 (6)</td><td colspan="1" rowspan="1" align="center" valign="top">163 &#x000b1; 4 (14)</td><td colspan="1" rowspan="1" align="center" valign="top">5.0 &#x000b1; 0.2 (9)</td><td colspan="1" rowspan="1" align="center" valign="top">5.8 &#x000b1; 0.2 (15)<xref ref-type="table-fn" rid="t1fn1">&#x02020;</xref></td><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top">13.8 &#x000b1; 0.2 (9)</td><td colspan="1" rowspan="1" align="center" valign="top">14.8 &#x000b1; 0.1 (13)<xref ref-type="table-fn" rid="t1fn1">&#x02020;</xref></td><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top">37.6 &#x000b1; 13.6 (9)</td><td colspan="1" rowspan="1" align="center" valign="top">23.5 &#x000b1; 4.8 (8)</td><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top">3.2 &#x000b1; 0.5 (8)</td><td colspan="1" rowspan="1" align="center" valign="top">2.6 &#x000b1; 0.2 (11)</td><td colspan="1" rowspan="1" align="center" valign="top"/></tr></tbody></table><table-wrap-foot><fn id="t1fn1"><label>&#x02020;</label><p>Data are means &#x000b1; SD (<italic>n</italic>). Because one-way ANOVAs revealed significant differences between PBS- and AngII-infused mice for all phenotypes (<italic>P</italic> &#x0003c; 0.05), these two groups were analyzed using separate two-way ANOVAs to identify statistically significant differences (<italic>P</italic> &#x0003c; 0.05) in factor level means due to genotype (gene), treatment (drug), or the interaction between genotype and treatment (interaction) for each parameter. Significant differences due to genotype</p></fn><fn id="t1fn2"><label>&#x02021;</label><p>or treatment effects between specific groups were determined by Bonferroni post hoc analyses. Cardiomyocyte diameter, ANP/glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and BNP/GAPDH data were transformed prior to analysis to account for differences in normality or SDs within these groups (see research design and methods).</p></fn><fn id="t1fn3"><label>&#x0002a;</label><p>SBP data were analyzed by both one- and two-way ANOVA. No significant differences were detected by either method.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="t2"><label>TABLE 2</label><caption><p>Cardiac hypertrophy in mPPAR&#x003b3; mice</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="2" align="center" valign="bottom">Treatment</th><th colspan="2" rowspan="1" align="center" valign="bottom">SBP (mmHg)<xref ref-type="table-fn" rid="t2fn1">&#x0002a;</xref><hr/></th><th colspan="3" rowspan="1" align="center" valign="bottom">Heart&#x02013;to&#x02013;body wt ratio(mg/g) <hr/></th><th colspan="3" rowspan="1" align="center" valign="bottom">Cardiomyocyte diameter (&#x003bc;m) <hr/></th></tr><tr><th colspan="1" rowspan="1" align="center" valign="bottom">WT</th><th colspan="1" rowspan="1" align="center" valign="bottom">KO</th><th colspan="1" rowspan="1" align="center" valign="bottom">WT</th><th colspan="1" rowspan="1" align="center" valign="bottom">KO</th><th colspan="1" rowspan="1" align="center" valign="bottom">Two-way ANOVA</th><th colspan="1" rowspan="1" align="center" valign="bottom">WT</th><th colspan="1" rowspan="1" align="center" valign="bottom">KO</th><th colspan="1" rowspan="1" align="center" valign="bottom">Two-way ANOVA</th></tr></thead><tbody><tr><td colspan="1" rowspan="1" align="left" valign="top">PBS&#x0002b;chow diet</td><td colspan="1" rowspan="1" align="center" valign="top">103 &#x000b1; 2 (15)</td><td colspan="1" rowspan="1" align="center" valign="top">108 &#x000b1; 3 (19)</td><td colspan="1" rowspan="1" align="center" valign="top">3.9 &#x000b1; 0.1 (9)</td><td colspan="1" rowspan="1" align="center" valign="top">4.1 &#x000b1; 0.1 (9)</td><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top">13.4 &#x000b1; 0.2 (9)</td><td colspan="1" rowspan="1" align="center" valign="top">13.7 &#x000b1; 0.2 (9)</td><td colspan="1" rowspan="1" align="center" valign="top"/></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">AngII&#x0002b;chow diet</td><td colspan="1" rowspan="1" align="center" valign="top">137 &#x000b1; 7 (7)</td><td colspan="1" rowspan="1" align="center" valign="top">148 &#x000b1; 4 (12)</td><td colspan="1" rowspan="1" align="center" valign="top">5.6 &#x000b1; 0.1 (9)</td><td colspan="1" rowspan="1" align="center" valign="top">5.4 &#x000b1; 0.1 (12)</td><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top">14.4 &#x000b1; 0.1 (9)</td><td colspan="1" rowspan="1" align="center" valign="top">14.4 &#x000b1; 0.2 (12)</td><td colspan="1" rowspan="1" align="center" valign="top"/></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">AngII&#x0002b;Pio</td><td colspan="1" rowspan="1" align="center" valign="top">141 &#x000b1; 8 (8)</td><td colspan="1" rowspan="1" align="center" valign="top">142 &#x000b1; 3 (9)</td><td colspan="1" rowspan="1" align="center" valign="top">5.9 &#x000b1; 0.2 (11)</td><td colspan="1" rowspan="1" align="center" valign="top">5.9 &#x000b1; 0.3 (9)</td><td colspan="1" rowspan="1" align="center" valign="top">Drug<xref ref-type="table-fn" rid="t2fn2">&#x02020;</xref></td><td colspan="1" rowspan="1" align="center" valign="top">14.6 &#x000b1; 0.1 (11)</td><td colspan="1" rowspan="1" align="center" valign="top">14.8 &#x000b1; 0.2 (9)</td><td colspan="1" rowspan="1" align="center" valign="top">Drug<xref ref-type="table-fn" rid="t2fn2">&#x02020;</xref></td></tr></tbody></table><table-wrap-foot><fn><p>Data are means &#x000b1; SD (<italic>n</italic>). PBS- and AngII-infused groups were analyzed separately because comparision between AngII- and PBS-infused groups revealed significant increases in all phenotypes upon AngII infusion (<italic>P</italic> &#x0003c; 0.05; one-way ANOVA). Differences in PBS&#x0002b;chow diet&#x02013;treated mice were analyzed with Student's <italic>t</italic> test. AngII-infused groups were analyzed with two-way ANOVAs to identify statistically significant differences (<italic>P</italic> &#x0003c; 0.05) in factor level means due to genotype (gene), treatment (drug), or the interaction between genotype and treatment (interaction), and Bonferroni post-test analyses were used to identify significant differences (<italic>P</italic> &#x0003c; 0.05) in parameter means due to genotype or treatment effects between specific groups. SBP and heart&#x02013;to&#x02013;body weight data from AngII-infused mice were transformed prior to analysis to account for differences in normality or SDs within these groups (see research design and methods). Both heart&#x02013;to&#x02013;body weight ratio and cardiomyocyte diameter values demonstrated significant differences due to treatment by two-way ANOVA, but no significant differences were detected between group means in the post hoc analyses.</p></fn><fn id="t2fn1"><label>&#x0002a;</label><p>SBP data were analyzed by both one- and two-way ANOVA. No significant differences were detected by either method.</p></fn><fn id="t2fn2"><label>&#x02020;</label><p>Two-way ANOVA comparing AngII&#x0002b;chow diet and AngII&#x0002b;Pio data.</p></fn></table-wrap-foot></table-wrap></floats-wrap></article> 